Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and debilitating side effect of numerous chemotherapeutic agents.
• Current treatment options for CIPN are limited, necessitating exploration of novel therapeutic approaches.
• There is a lack of published literature investigating the use of topical cannabinoids for managing CIPN.

Purpose of the Study:

• To present a case series on the use of topical cannabinoids for patients experiencing CIPN.
• To explore the potential mechanisms by which cannabinoids might alleviate CIPN symptoms.
• To lay the groundwork for future randomized controlled trials on topical cannabinoid efficacy.

Main Methods:

• A case series was conducted involving patients with CIPN from oncology clinics at Sutter Health, CA, and Mayo Clinic, Rochester, MN.
• Data were collected from April 2019 to December 2020.
• Patients in the case series used topical creams containing delta-nine-tetrahydrocannabinol (THC) and/or cannabidiol (CBD).

Main Results:

• The case series suggests that topical cannabinoid formulations may offer relief for patients suffering from CIPN.
• Observations indicate potential benefits in alleviating established CIPN symptoms.
• The study highlights the need for further investigation into the therapeutic role of cannabinoids.

Conclusions:

• Topical cannabinoids present a potential adjunctive therapy for chemotherapy-induced peripheral neuropathy.
• Further research, including a randomized placebo-controlled trial, is warranted to establish the efficacy of standardized topical cannabinoid products for CIPN.
• Understanding the mechanisms of action is crucial for optimizing cannabinoid-based treatments for neuropathy.